chartexchange

CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026

GlobeNewswire Inc. | Nov 9, 2026 9:16 AM EST

-Data presented in a late-breaking oral presentation at AHA-

Read original article